Global Trends in CD4 Cell Count at the Start of Antiretroviral Therapy: Collaborative Study of Treatment Programs

被引:96
|
作者
Anderegg, Nanina [1 ]
Panayidou, Klea [1 ]
Abo, Yao [2 ]
Alejos, Belen [3 ]
Althoff, Keri N. [4 ]
Anastos, Kathryn [5 ,6 ]
Antinori, Andrea [7 ]
Balestre, Eric [8 ]
Becquet, Renaud [9 ,10 ]
Castagna, Antonella [11 ]
Castelnuovo, Barbara [12 ]
Chene, Genevieve [13 ]
Coelho, Lara [14 ]
Collins, Intira Jeannie [15 ]
Costagliola, Dominique [16 ]
Crabtree-Ramirez, Brenda [17 ]
Dabis, Francois [18 ,19 ]
Monforte, Antonella d'Arminio [20 ]
Davies, Mary-Ann [21 ]
De Wit, Stephane [22 ]
Delpech, Valerie [23 ]
De La Mata, Nicole L. [24 ]
Duda, Stephany [25 ]
Freeman, Aimee [4 ]
Gange, Stephen J. [4 ]
Grabmeier-Pfistershammer, Katharina [26 ]
Gunsenheimer-Bartmeyer, Barbara [27 ]
Jiamsakul, Awachana [24 ]
Kitahata, Mari M. [28 ]
Law, Matthew
Manzardo, Christian [29 ]
McGowan, Catherine [30 ]
Meyer, Laurence [31 ]
Moore, Richard [32 ]
Mussini, Cristina [33 ]
Nakigoz, Gertrude [34 ]
Nash, Denis [35 ,36 ]
Ng, Oon Tek [37 ]
Obel, Niels [38 ]
Pantazis, Nikos [39 ]
Poda, Armel [40 ]
Raben, Dorthe [38 ]
Reiss, Peter [41 ,42 ,43 ]
Riggen, Larry [44 ]
Sabin, Caroline [45 ]
Sinayobye, Jean d'Amour [46 ]
Sonnerborg, Anders [47 ,48 ]
Stoeckle, Marcel [49 ,50 ]
Thorne, Claire [51 ]
Torti, Carlo [52 ]
机构
[1] Univ Bern, Inst Social & Prevent Med, Finkenhubelweg 11, CH-3012 Bern, Switzerland
[2] Ctr Hosp Univ Treichville, Programme PAC CI, Abidjan, Cote Ivoire
[3] Inst Salud Carlos III, Natl Ctr Epidemiol, Madrid, Spain
[4] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA
[5] Albert Einstein Coll Med, Dept Med, Bronx, NY 10467 USA
[6] Albert Einstein Coll Med, Dept Epidemiol & Populat Hlth, Bronx, NY 10467 USA
[7] IRCCS, Natl Inst Infect Dis L Spallanzani, HIV AIDS Dept, Rome, Italy
[8] Univ Bordeaux, Bordeaux Populat Hlth, Ctr INSERM U1219, Bordeaux, France
[9] Univ Bordeaux, INSERM, Ctr Rech, U1219, Bordeaux, France
[10] Univ Bordeaux, Inst Sante Publ Epidemiol Dev, Bordeaux, France
[11] Univ Vita Salute San Raffaele, Dept Infect Dis, San Raffaele Sci Inst, Milan, Italy
[12] Makerere Univ, Infect Dis Inst, Mulago Hosp, Kampala, Uganda
[13] INSERM, ISPED, Ctr INSERM, U1219 Bordeaux Populat Hlth, Bordeaux, France
[14] Fundacao Oswaldo Cruz, Inst Pesquisa Clin Evandro Chagas, Rio De Janeiro, Brazil
[15] UCL, Inst Clin Trials & Methodol, MRC, Clin Trials Unit, London, England
[16] Univ Paris 06, UPMC, Sorbonne Univ, INSERM,Inst Pierre Louis Epidemiol & Sante Publ, Paris, France
[17] Inst Nacl Ciencias Med Nutr Salvador Zubiran, Dept Infect Dis, Mexico City, DF, Mexico
[18] Univ Bordeaux, INSERM, Ctr Rech, INSERM,U1219, Bordeaux, France
[19] Univ Bordeaux, Inst Sante Publ Epidemiol Dev, Bordeaux, France
[20] Univ Milan, Dept Hlth Sci, Clin Infect & Trop Dis, ASST Santi Paolo & Carlo, Milan, Italy
[21] Univ Cape Town, Sch Publ Hlth & Family Med, Ctr Infect Dis Epidemiol & Res, Cape Town, South Africa
[22] Univ Libre Bruxelles, St Pierre Univ Hosp, Dept Infect Dis, Brussels, Belgium
[23] Publ Hlth England, London, England
[24] UNSW Sydney, Kirby Inst, Sydney, NSW, Australia
[25] Vanderbilt Univ, Med Ctr, Dept Biomed Informat, Nashville, TN USA
[26] Med Univ Vienna, Div Immunol Allergy & Infect Dis, Vienna, Austria
[27] Robert Koch Inst, Berlin, Germany
[28] Univ Washington, Ctr AIDS Res, Seattle, WA 98195 USA
[29] Univ Barcelona, Hosp Clin IDIBAPS, Infect Dis Serv, Barcelona, Spain
[30] Vanderbilt Univ, Med Ctr, Div Infect Dis, 221 Kirkland Hall, Nashville, TN 37235 USA
[31] Univ Paris Sud, Le Kremlin Bicetre, France
[32] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Med, Baltimore, MD USA
[33] Univ Modena & Reggio Emilia, Clin Infect Dis, Modena, Italy
[34] Rakai Hlth Sci Program, Kalisizo, Uganda
[35] CUNY, Inst Implementat Sci Populat Hlth, New York, NY USA
[36] CUNY, Grad Sch Publ Hlth & Hlth Policy, New York, NY USA
[37] Tan Tock Seng Hosp, Singapore, Singapore
[38] Univ Copenhagen, Dept Infect Dis, Rigshosp, Copenhagen, Denmark
[39] Natl & Kapodistrian Univ Athens, Med Sch, Dept Hyg Epidemiol & Med Stat, Athens, Greece
[40] Univ Polytech Bobo Dioulasso, Inst Super Sci Sante, Bobo Dioulasso, Burkina Faso
[41] Univ Amsterdam, Acad Med Ctr, Stichting HIV Monitoring, Amsterdam, Netherlands
[42] Univ Amsterdam, Dept Global Hlth, Acad Med Ctr, Amsterdam, Netherlands
[43] Univ Amsterdam, Div Infect Dis, Acad Med Ctr, Amsterdam, Netherlands
[44] Indiana Univ, Fairbanks Sch Publ Hlth, Dept Biostat, Indianapolis, IN USA
[45] UCL, Res Dept Infect & Populat Hlth, London, England
[46] Rwanda Mil Hosp, Div Res & Clin Educ, Kanombe, Kigali, Rwanda
[47] Karolinska Inst, Stockholm, Sweden
[48] Karolinska Univ Hosp, Stockholm, Sweden
[49] Univ Basel Hosp, Div Infect Dis & Hosp Epidemiol, Basel, Switzerland
[50] Univ Basel, Basel, Switzerland
基金
美国医疗保健研究与质量局; 加拿大健康研究院; 英国医学研究理事会;
关键词
antiretroviral therapy; CD4 cell count; WHO guidelines; INTERNATIONAL EPIDEMIOLOGIC DATABASES; ADVANCED HIV DISEASE; EVALUATE AIDS IEDEA; COHORT PROFILE; INITIATION; CARE; GUIDELINES;
D O I
10.1093/cid/cix915
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
We modeled global time trends in median CD4 cell counts at combination antiretroviral therapy initiation in human immunodeficiency virus-infected adults. These counts have increased in all country income groups since 2002 but generally remained below 350/mu L in 2015.Early initiation of combination antiretroviral therapy (cART), at higher CD4 cell counts, prevents disease progression and reduces sexual transmission of human immunodeficiency virus (HIV). We describe the temporal trends in CD4 cell counts at the start of cART in adults from low-income, lower-middle-income, upper-middle-income, and high-income countries (LICs, LMICs, UMICs, and HICs, respectively). We included HIV-infected individuals aged a parts per thousand<yen>16 years who started cART between 2002 and 2015 in a clinic participating in the International epidemiology Databases to Evaluate AIDS (IeDEA) or the Collaboration of Observational HIV Epidemiological Research in Europe (COHERE). Missing CD4 cell counts at the start of cART were estimated through multiple imputation. Weighted mixed-effect models were used to smooth trends in median CD4 cell counts. A total of 951855 adults from 16 LICs, 11 LMICs, 9 UMICs, and 19 HICs were included. Overall, the modeled median CD4 cell count at the start of cART increased from 2002 to 2015, from 78/A mu L (95% confidence interval, 58-104/A mu L) to 287/A mu L (250-328/A mu L) in LICs, from 99/A mu L (71-140/A mu L) to 234/A mu L (192-285/A mu L) in LMICs, from 71/A mu L (49-104/A mu L) to 311/A mu L (255-379/A mu L) in UMICs, and from 161/A mu L (143-181/A mu L) to 327/A mu L (286-372/A mu L) in HICs. In LICs, LMICs, and UMICs, the increase was more pronounced in women; in HICs, the opposite was observed. Median CD4 cell counts at the start of cART increased in all income groups, but generally remained below 350/mu L in 2015. Substantial additional efforts and resources are required to achieve earlier diagnosis, linkage to care, and initiation of cART.
引用
收藏
页码:893 / 903
页数:11
相关论文
共 50 条
  • [1] Global Trends in CD4 Count Measurement and Distribution at First Antiretroviral Treatment Initiation
    de Waal, Renee
    Wools-Kaloustian, Kara
    Brazier, Ellen
    Althoff, Keri N.
    Jaquet, Antoine
    Duda, Stephany N.
    Kumarasamy, Nagalingeswaran
    Savory, Theodora
    Byakwaga, Helen
    Murenzi, Gad
    Justice, Amy
    Ekouevi, Didier K.
    Cesar, Carina
    Pasayan, Mark K. U.
    Thawani, Agness
    Kasozi, Charles
    Babakazo, Pelagie
    Karris, Maile
    Messou, Eugene
    Cortes, Claudia P.
    Kunzekwenyika, Cordelia
    Choi, Jun Yong
    Owarwo, Noela C.
    Niyongabo, Annabelle
    Marconi, Vincent C.
    Ezechi, Oliver
    Castilho, Jessica L.
    Petoumenos, Kathy
    Johnson, Leigh F.
    Ford, Nathan
    Kassanjee, Reshma
    CLINICAL INFECTIOUS DISEASES, 2024,
  • [2] Mortality According to CD4 Count at Start of Combination Antiretroviral Therapy Among HIV-infected Patients Followed for up to 15 Years After Start of Treatment: Collaborative Cohort Study
    May, Margaret T.
    Vehreschild, Jorg-Janne
    Trickey, Adam
    Obel, Niels
    Reiss, Peter
    Bonnet, Fabrice
    Mary-Krause, Murielle
    Samji, Hasina
    Cavassini, Matthias
    Gill, Michael John
    Shepherd, Leah C.
    Crane, Heidi M.
    Monforte, Antonella d'Arminio
    Burkholder, Greer A.
    Johnson, Margaret M.
    Sobrino-Vegas, Paz
    Domingo, Pere
    Zangerle, Robert
    Justice, Amy C.
    Sterling, Timothy R.
    Miro, Jose M.
    Sterne, Jonathan A. C.
    CLINICAL INFECTIOUS DISEASES, 2016, 62 (12) : 1571 - 1577
  • [3] The future role of CD4 cell count for monitoring antiretroviral therapy
    Ford, Nathan
    Meintjes, Graeme
    Pozniak, Anton
    Bygrave, Helen
    Hill, Andrew
    Peter, Trevor
    Davies, Mary-Ann
    Grinsztejn, Beatriz
    Calmy, Alexandra
    Kumarasamy, N.
    Phanuphak, Praphan
    deBeaudrap, Pierre
    Vitoria, Marco
    Doherty, Meg
    Stevens, Wendy
    Siberry, George K.
    LANCET INFECTIOUS DISEASES, 2015, 15 (02) : 241 - 247
  • [4] Estimating the Optimal CD4 Count for HIV-infected Persons to Start Antiretroviral Therapy
    Shepherd, Bryan E.
    Jenkins, Cathy A.
    Rebeiro, Peter F.
    Stinnette, Samuel E.
    Bebawy, Sally S.
    McGowan, Catherine C.
    Hulgan, Todd
    Sterling, Timothy R.
    EPIDEMIOLOGY, 2010, 21 (05) : 698 - 705
  • [5] Is there a baseline CD4 cell count that precludes a survival response to modern antiretroviral therapy?
    Wood, E
    Hogg, RS
    Yip, B
    Harrigan, PR
    O'Shaughnesy, MV
    Montaner, JSG
    AIDS, 2003, 17 (05) : 711 - 720
  • [6] Targeting antiretroviral therapy: Lessons from a longitudinal study of morbidity and treatment in relation to CD4 count in Thailand
    Teerawattananon, Y.
    Hanshaoworakul, W.
    Russell, S.
    Tangcharoensathien, V.
    Jiamton, S.
    ASIA-PACIFIC JOURNAL OF PUBLIC HEALTH, 2006, 18 (01) : 39 - 48
  • [7] Challenges in initiating antiretroviral therapy for all HIV-infected people regardless of CD4 cell count
    Bigna, Jean Joel R.
    Plottel, Claudia S.
    Koulla-Shiro, Sinata
    INFECTIOUS DISEASES OF POVERTY, 2016, 5
  • [8] Alcohol Consumption and CD4 T-Cell Count Response Among Persons Initiating Antiretroviral Therapy
    Kowalski, Stefan
    Colantuoni, Elizabeth
    Lau, Bryan
    Keruly, Jeanne
    McCaul, Mary E.
    Hutton, Heidi E.
    Moore, Richard D.
    Chander, Geetanjali
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2012, 61 (04) : 455 - 461
  • [9] The impact of episodic CD4 cell count-guided antiretroviral therapy on quality of life
    Burman, William J.
    Grund, Birgit
    Roedige, Mollie P.
    Friedland, Gerald
    Darhyshire, Janet
    Wu, Albert W.
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2008, 47 (02) : 185 - 193
  • [10] Changes in the slope of the CD4 cell count increase after initiation of potent antiretroviral treatment
    Bosch, Ronald J.
    Wang, Rui
    Vaida, Florin
    Lederman, Michael M.
    Albrecht, Mary A.
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2006, 43 (04) : 433 - 435